Centene (CNC, Health insurers) Stock Valuation & Fair Value Mixed on our tests
Centene (CNC, Health insurers) trades at a current P/E of 15.5, about 10% below its historical normal valuation, with a forward growth estimate of 21.0% and a PEG of 0.74. Analysts' one-year estimates have been hit 64% of the time. Priced at its historical normal P/E of 17.2 on the same blended earnings, the 2026-10-09 close of $65.36 corresponds to about $72.60 a share. This is a valuation reference, not a price target.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation and forecast return, and for the top ratings, credit rating, growth and analyst accuracy.
- Price $67.02 at the 2026-10-12 close, 4.6% above the 20-day average ($64.08) and 3.1% above the 50-day ($65.00).
- RSI (14) at 59.6.
- 52-week range $31.80 to $69.41: the price is 3.4% below the high and 110.8% above the low.
The Street vs SeerForecast
Wall Street's mean price target for CNC is $71.78 across 18 analysts, 7.1% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating moved from trading above its usual valuation (2026-06-03) to mixed on our tests (2026-10-12).
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 39 weeks
Frequently asked questions
Is Centene stock overvalued?
At a current P/E of 15.5 versus its historical normal P/E of 17.2, Centene trades about 10% below its typical valuation, with a PEG of 0.74 on 21.0% forward growth. tickerseer currently rates it mixed on our tests.
What is Centene's fair value and PEG?
Centene trades at a current P/E of 15.5 against a historical normal P/E of 17.2, a PEG of 0.74, and a forward growth estimate of 21.0%. Priced at its historical normal P/E of 17.2 on the same blended earnings, the 2026-10-09 close of $65.36 corresponds to about $72.60 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Centene changed?
tickerseer's rating moved from trading above its usual valuation (2026-06-03) to mixed on our tests (2026-10-12).
What is the analyst price target for Centene?
The mean Wall Street price target for Centene is $71.78 across 18 analysts, 7.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health insurers. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.